These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 28299751)

  • 1. Maurie Markman on the Groundbreaking TAPUR Trial.
    Markman M
    Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751
    [No Abstract]   [Full Text] [Related]  

  • 2. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is Precision Medicine an Oxymoron?
    Eckhardt SG; Lieu C
    JAMA Oncol; 2019 Feb; 5(2):142-143. PubMed ID: 30419105
    [No Abstract]   [Full Text] [Related]  

  • 4. How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy.
    Farwell MD; Clark AS; Mankoff DA
    JAMA Oncol; 2015 Jul; 1(4):421-2. PubMed ID: 26181243
    [No Abstract]   [Full Text] [Related]  

  • 5. New ESMO scale ranks mutations as cancer medicine targets.
    Fricker J
    Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
    [No Abstract]   [Full Text] [Related]  

  • 6. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
    Blumenthal GM; Mansfield E; Pazdur R
    JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeted therapy: a potential oversight in trial protocol.
    Moorthy T
    Lancet Oncol; 2018 Sep; 19(9):e439. PubMed ID: 30191846
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using Somatic Mutations to Guide Treatment Decisions: Context Matters.
    Horlings HM; Shah SP; Huntsman DG
    JAMA Oncol; 2015 Jun; 1(3):275-6. PubMed ID: 26181166
    [No Abstract]   [Full Text] [Related]  

  • 10. Methodology of clinical trials in lung cancer.
    Menis J; Besse B; Lacombe D
    Chin Clin Oncol; 2015 Dec; 4(4):44. PubMed ID: 26730756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of intratumour heterogeneity for treatment stratification.
    Crockford A; Jamal-Hanjani M; Hicks J; Swanton C
    J Pathol; 2014 Jan; 232(2):264-73. PubMed ID: 24115146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalising the treatment of prostate cancer.
    Gunjur A
    Lancet Oncol; 2015 Dec; 16(16):e592. PubMed ID: 26549591
    [No Abstract]   [Full Text] [Related]  

  • 13. Giving Up on Precision Oncology? Not So Fast!
    Warner JL
    Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
    [No Abstract]   [Full Text] [Related]  

  • 14. Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques--the Usefulness in the Qualification of Cancer Patients for Molecularly-Targeted Therapies.
    Nicoś M; Wojas-Krawczyk K; Krawczyk P; Milanowski J
    Adv Clin Exp Med; 2015; 24(4):715-23. PubMed ID: 26469118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third-Line Treatment Options for Kidney Cancer.
    Posadas EM; Limvorasak S; Figlin RA
    Oncology (Williston Park); 2016 Sep; 30(9):813-5. PubMed ID: 27633411
    [No Abstract]   [Full Text] [Related]  

  • 16. Brave-ish New World--What's Needed to Make Precision Oncology a Practical Reality.
    MacConaill LE; Lindeman NI; Rollins BJ
    JAMA Oncol; 2015 Oct; 1(7):879-80. PubMed ID: 26181886
    [No Abstract]   [Full Text] [Related]  

  • 17. The evolving potential of companion diagnostics.
    Khoury JD
    Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivering on the promise of precision cancer medicine.
    Berger MF; Van Allen EM
    Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
    [No Abstract]   [Full Text] [Related]  

  • 19. Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice.
    Beer PA; Cooke SL; Chang DK; Biankin AV
    Ann Oncol; 2019 Nov; 30(11):1691-1694. PubMed ID: 31665210
    [No Abstract]   [Full Text] [Related]  

  • 20. Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.
    Eke I; Makinde AY; Aryankalayil MJ; Ahmed MM; Coleman CN
    Cancer Lett; 2016 Nov; 382(1):118-126. PubMed ID: 26828133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.